nimodipine has been researched along with Disease Exacerbation in 6 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disease progression was assessed by repeated computerized measurements of isometric force from 20 muscle groups, and calculation of global force score." | 6.67 | Can nimodipine affect progression of motor neuron disease? A double-blind pilot study. ( Abraham, M; Achiron, A; Djaldetti, R; Melamed, E; Ziv, I, 1994) |
| "Disease progression was assessed by repeated computerized measurements of isometric force from 20 muscle groups, and calculation of global force score." | 2.67 | Can nimodipine affect progression of motor neuron disease? A double-blind pilot study. ( Abraham, M; Achiron, A; Djaldetti, R; Melamed, E; Ziv, I, 1994) |
| "Treatment with nimodipine restores spinal oxygenation and can rapidly improve function." | 1.56 | Nimodipine Reduces Dysfunction and Demyelination in Models of Multiple Sclerosis. ( Davies, AL; Del Rossi, N; Desai, RA; Dyson, A; Golay, X; Gustavson, B; Harvey, AR; Kaynezhad, P; Linington, C; Mackenzie, L; McElroy, D; Schiza, D; Singer, M; Smith, KJ; Tachrount, M; Tachtsidis, I; van der Putten, MA, 2020) |
| "In aneurysmal subarachnoid haemorrhage cerebral vasospasm leads to clinical worsening and poor outcome." | 1.46 | Clinical Course and Monitoring Parameters After Continuous Interventional Intra-Arterial Treatment in Patients with Refractory Cerebral Vasospasm. ( Doukas, A; Jansen, O; Larsen, N; Mehdorn, M; Stopfer, A; Synowitz, M; von der Brelie, C, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hawkes, MA | 1 |
| Hlavnicka, AA | 1 |
| Wainsztein, NA | 1 |
| Desai, RA | 1 |
| Davies, AL | 1 |
| Del Rossi, N | 1 |
| Tachrount, M | 1 |
| Dyson, A | 1 |
| Gustavson, B | 1 |
| Kaynezhad, P | 1 |
| Mackenzie, L | 1 |
| van der Putten, MA | 1 |
| McElroy, D | 1 |
| Schiza, D | 1 |
| Linington, C | 1 |
| Singer, M | 1 |
| Harvey, AR | 1 |
| Tachtsidis, I | 1 |
| Golay, X | 1 |
| Smith, KJ | 1 |
| Cai, X | 1 |
| Bhattacharyya, S | 1 |
| Plitt, A | 1 |
| Raibagkar, P | 1 |
| LaBuzetta, JN | 1 |
| Schleicher, SM | 1 |
| Munshi, NC | 1 |
| Klein, JP | 1 |
| von der Brelie, C | 1 |
| Doukas, A | 1 |
| Stopfer, A | 1 |
| Larsen, N | 1 |
| Mehdorn, M | 1 |
| Synowitz, M | 1 |
| Jansen, O | 1 |
| Bean, BP | 1 |
| Ziv, I | 1 |
| Achiron, A | 1 |
| Djaldetti, R | 1 |
| Abraham, M | 1 |
| Melamed, E | 1 |
1 trial available for nimodipine and Disease Exacerbation
| Article | Year |
|---|---|
Can nimodipine affect progression of motor neuron disease? A double-blind pilot study.
Topics: Administration, Oral; Calcium Channel Blockers; Cross-Over Studies; Disease Progression; Double-Blin | 1994 |
5 other studies available for nimodipine and Disease Exacerbation
| Article | Year |
|---|---|
Reversible Cerebral Vasoconstriction Syndrome Responsive to Intravenous Milrinone.
Topics: Adult; Angiography, Digital Subtraction; Aphasia, Broca; Brain Edema; Cerebral Hemorrhage; Computed | 2020 |
Nimodipine Reduces Dysfunction and Demyelination in Models of Multiple Sclerosis.
Topics: Animals; Calcium Channel Blockers; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; | 2020 |
Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma.
Topics: Anticonvulsants; Antihypertensive Agents; Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; Brai | 2016 |
Clinical Course and Monitoring Parameters After Continuous Interventional Intra-Arterial Treatment in Patients with Refractory Cerebral Vasospasm.
Topics: Cerebral Angiography; Chronic Disease; Disease Progression; Echoencephalography; Female; Humans; Inf | 2017 |
Neurophysiology: stressful pacemaking.
Topics: Animals; Antiparkinson Agents; Calcium; Calcium Channels, L-Type; Disease Models, Animal; Disease Pr | 2007 |